<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976309</url>
  </required_header>
  <id_info>
    <org_study_id>19734A</org_study_id>
    <nct_id>NCT04976309</nct_id>
  </id_info>
  <brief_title>A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects</brief_title>
  <official_title>Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Investigating the Effect of Lu AG09222 on PACAP38- and VIP-induced Vasodilation, Heart Rate Increase, and Headache in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how well Lu AG09222 can prevent blood vessel&#xD;
      dilation in a headache model.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the effect of preventive treatment with Lu AG09222 on&#xD;
      vasodilation, heart rate increase, and headache induced by PACAP and VIP.&#xD;
&#xD;
      Subjects will be randomised to three arms, placebo + saline, placebo + VIP and PACAP, and Lu&#xD;
      AG09222 + VIP and PACAP. Subjects who complete the study will attend a safety follow-up visit&#xD;
      at 10 to 12 weeks after administration of investigational medicinal product.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">December 3, 2021</completion_date>
  <primary_completion_date type="Actual">September 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of change from start of infusion in superficial temporal artery (STA) diameter from 0 to 120 min after start of infusion of PACAP38</measure>
    <time_frame>0 to 120 min after infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from start of infusion in STA diameter to 60 min after start of infusion of PACAP38</measure>
    <time_frame>0 to 60 min after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum change from start of infusion in STA diameter between 0 and 120 min after start of infusion of PACAP38</measure>
    <time_frame>0 and 120 min after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC in change from start of infusion in facial blood flow from 0 to 120 min after start of infusion of PACAP38</measure>
    <time_frame>0 to 120 min after infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC in change from start of infusion in heart rate from 0 to 120 min after start of infusion of PACAP38</measure>
    <time_frame>0 to 120 min after infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo + saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + VIP and PACAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AG09222 + VIP and PACAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lu AG09222, single dose intravenous infusion over 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG09222</intervention_name>
    <description>Single dose</description>
    <arm_group_label>Lu AG09222 + VIP and PACAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose</description>
    <arm_group_label>Placebo + VIP and PACAP</arm_group_label>
    <arm_group_label>Placebo + saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has a body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2, and a body weight ≥&#xD;
             45 and ≤ 95 kg at the screening visit.&#xD;
&#xD;
          -  The subject is, in the opinion of the investigator, generally healthy based on medical&#xD;
             history, a physical examination, vital signs, an ECG, and the results of the clinical&#xD;
             chemistry, haematology, urinalysis, serology, and other laboratory tests at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject fulfils the diagnostic criteria for a primary headache disorder, or has a&#xD;
             first degree relative with a primary headache disorder, according to the International&#xD;
             Headache Society (IHS) International Classification of Headache Disorders 3rd edition&#xD;
             (ICHD-3), except tension-type headache.&#xD;
&#xD;
          -  The subject has or has had tension-type headache more than once per month on average&#xD;
             during the 6 months prior to the screening visit.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Headache Center Rigshospitalet Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

